Tel Aviv, Israel, Mainz, Germany, December 17th, Tel Aviv University (TAU) through Ramot, its Business Engagement Center, and BioNTech RNA Pharmaceuticals GmbH, a leader in the development of precise and individualized immunotherapies with a broad and rapidly growing clinical pipeline today announced, that they have entered into a license agreement to further explore a set of novel lipids for improved mRNA delivery in various therapeutic indications.
Under the terms of the agreement, BioNTech gains full access to an undisclosed number of lipids developed by Professor Dr. Dan Peer, Managing Director Center for Translational Medicine and Chair Cancer Biology Research Center at Tel Aviv University, for use in ribonucleic acid (RNA) formulations. Financial terms of the agreement were not disclosed. The lipids developed by Prof. Peer provide delivery solutions for all nucleic acid based therapies and enable as well the entrapment of payloads with very large molecular mass (over 10Kb).
„The agreement will give us access to lipids from Ramot that complement BioNTech’s existing mRNA delivery technologies,” said Prof. Dr. Ugur Sahin, Co-Founder and Chief Executive Officer of BioNTech. “Novel lipid compositions enable us to diversify our application portfolio, especially when there is a need to carry large payloads for genome editing and additions in rare diseases, cancer therapy and many other indications.”
„We are proud to have BioNTech as a licensing partner to further evaluate the use of our novel lipids which we are developing under our Tel Aviv University Technology Innovation Momentum Fund program,” said Shlomo Nimrodi, Chief Executive Officer of Ramot.
About Tel Aviv University
Tel Aviv University (TAU) - Israel's largest and most comprehensive institution of higher learning - is home to over 30,000 students studying in nine faculties and over 125 schools and departments across the spectrum of sciences, humanities and the arts. Situated in Israel's cultural, financial and technological capital, TAU shares Tel Aviv's unshakable spirit of openness and innovation – and boasts a campus life as dynamic and pluralistic as the metropolis itself. Tel Aviv the city and Tel Aviv the university are one and the same – a thriving Mediterranean center of diversity and discovery. Consistently ranked in the top 20 in the world in terms of scientific citations and among the top 100 universities internationally, Tel Aviv University is also Israel's first choice for students, and its graduates are the most sought after by Israeli companies.
About Ramot at Tel Aviv University
Ramot is the Business Engagement Center at Tel Aviv University, Israel's largest research and teaching university. Founded in 1956, Tel Aviv University is located in Israel's cultural, financial and industrial center. Rooted in both academic and corporate arenas, Ramot is uniquely positioned to cultivate the special relationships between these two compelling worlds, creating win-win connections that support
fertile, ground breaking research while providing companies with discoveries that give them a crucial competitive edge. For more information, visit http://www.ramot.org.
Media Contact – Ramot at Tel Aviv University
Maya Kotler, +972.52.605 7144
BioNTech is Europe’s largest privately-held biopharmaceutical company pioneering the development of more precise and individualized therapies for cancer and the prevention of infectious diseases. The Company combines all building blocks for more precise and individualized immunotherapies under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based product candidates through innovative chimeric antigen receptors and T-cell receptor-based compounds to novel checkpoint immunomodulators and small molecules. BioNTech’s commercial approach is validated by seven corporate partnerships with Genentech a member of the Roche Group, Pfizer, Genmab, Eli Lilly and Company, Sanofi, Genevant and Bayer Animal Health and its scientific approach through over 60 peer-reviewed scientific publications, including five publications in Nature. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. www.biontech.de.
For more information, please contact:
Head Global Communications
Tel: +49 (0) 171 980 1089